ImmunityBio (IBRX) Preferred Stock Liabilities (2023 - 2026)
ImmunityBio (IBRX) posted quarterly Preferred Stock Liabilities of $23.3 million for Q1 2026, up 13.49% year-over-year from $20.5 million in Q1 2025, and up 18.21% quarter-over-quarter from $19.7 million in Q4 2025.
ImmunityBio (IBRX) Preferred Stock Liabilities (2023 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Preferred Stock Liabilities for 4 consecutive years, with $23.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Preferred Stock Liabilities rose 13.49% year-over-year to $23.3 million; the TTM figure through Mar 2026 stood at $23.3 million (up 13.49% YoY), while the FY2025 annual figure was $19.7 million, down 24.49% from the prior year.
- Preferred Stock Liabilities improved to $23.3 million in Q1 2026 per IBRX's latest filing, from $19.7 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $37.9 million in Q1 2024 and bottomed at $18.3 million in Q3 2025.
- Historically, Preferred Stock Liabilities has averaged $24.0 million across 4 years, with a median of $20.7 million in 2024.
- Annual changes were most pronounced in 2025 — Preferred Stock Liabilities sank 45.84% — and 2026, when it gained 13.49%.
- ImmunityBio's Preferred Stock Liabilities stood at $35.3 million in 2023, then fell by 26.07% to $26.1 million in 2024, then retreated by 24.49% to $19.7 million in 2025, then rose by 18.21% to $23.3 million in 2026.
- Business Quant data shows IBRX's Preferred Stock Liabilities at $23.3 million in Q1 2026, $19.7 million in Q4 2025, and $18.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | 24.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.01 Mn |
| Mar 31, 2026 | 23.31 Mn |
| Dec 31, 2025 | 19.72 Mn |
| Sep 30, 2025 | 18.32 Mn |
| Jun 30, 2025 | 18.61 Mn |
| Mar 31, 2025 | 20.54 Mn |
| Dec 31, 2024 | 26.12 Mn |
| Sep 30, 2024 | 19.22 Mn |
| Jun 30, 2024 | 20.81 Mn |
| Mar 31, 2024 | 37.93 Mn |
| Dec 31, 2023 | 35.33 Mn |